Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| KYNTRA BIO, INC.FGEN · Entity 7431 | Director | June 05, 2019 | June 07, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
KYNTRA BIO, INC.
Report date June 05, 2019 · Filed June 07, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 56,400 |
Reported balance
After 2019-06-05 transaction · row 1
1 source rowRow 1 · 2019-06-05 · Grant · Acquired 4,700 · Balance 56,400 F1: Represents the grant of restricted stock units that vest on the earlier of June 5, 2020 or the date of the next annual meeting of stockholders. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.03 · Expires 2029-06-05 | Direct | 7,800 |
Reported balance
After 2019-06-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-06-05 · Grant · Acquired 7,800 · Balance 7,800 F2: Options vest on the earlier of June 5, 2020 or the date of the next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of restricted stock units that vest on the earlier of June 5, 2020 or the date of the next annual meeting of stockholders.
F2: Options vest on the earlier of June 5, 2020 or the date of the next annual meeting of stockholders.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2019 Filed Jun 7, 2019 23:26 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantStock Option (Right to Buy) · Derivative | 7,800 | $0.00 Strike: $39.03 | $0.00 |
DisclosureSEC source: 0001209191-19-035670 · doc4.xml · derivative · entry 2 Tamura Toshinari · CIK 0001621329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,800 Underlying: Common Stock · 7,800 shares Expires 2029-06-05 F2 · derivative.exercise_date: Options vest on the earlier of June 5, 2020 or the date of the next annual meeting of stockholders. Read SEC document |
| June 05, 2019 Filed Jun 7, 2019 23:26 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantCommon Stock | 4,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-035670 · doc4.xml · nonDerivative · entry 1 Tamura Toshinari · CIK 0001621329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,400 F1 · shares: Represents the grant of restricted stock units that vest on the earlier of June 5, 2020 or the date of the next annual meeting of stockholders. Read SEC document |
| August 22, 2018 Filed Aug 24, 2018 23:25 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $19.05 | $0.00 |
DisclosureSEC source: 0001209191-18-048435 · doc4.xml · derivative · entry 3 Tamura Toshinari · CIK 0001621329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2026-06-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested. Read SEC document |
| August 22, 2018 Filed Aug 24, 2018 23:25 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 12,000 | $60.65 | $727,800.00 |
DisclosureSEC source: 0001209191-18-048435 · doc4.xml · nonDerivative · entry 2 Tamura Toshinari · CIK 0001621329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,700 Read SEC document |
| August 22, 2018 Filed Aug 24, 2018 23:25 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 12,000 | $19.05 | $228,600.00 |
DisclosureSEC source: 0001209191-18-048435 · doc4.xml · nonDerivative · entry 1 Tamura Toshinari · CIK 0001621329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 23:45 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $55.30 | $0.00 |
DisclosureSEC source: 0001209191-18-036522 · doc4.xml · derivative · entry 2 Tamura Toshinari · CIK 0001621329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2028-06-05 F2 · derivative.exercise_date: Options vest on the earlier of June 6, 2019 or the date of next annual meeting of stockholders. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 23:45 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantCommon Stock | 3,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-036522 · doc4.xml · nonDerivative · entry 1 Tamura Toshinari · CIK 0001621329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,700 F1 · shares: Represents the grant of restricted stock units that vest on the earlier of June 6, 2019 or the date of the next annual meeting of stockholders. Read SEC document |
| March 13, 2018 Filed Mar 16, 2018 00:14 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $18.34 | $0.00 |
DisclosureSEC source: 0001209191-18-020025 · doc4.xml · derivative · entry 6 Tamura Toshinari · CIK 0001621329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2025-06-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested. Read SEC document |
| March 13, 2018 Filed Mar 16, 2018 00:14 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001209191-18-020025 · doc4.xml · derivative · entry 5 Tamura Toshinari · CIK 0001621329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2024-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested. Read SEC document |
| March 13, 2018 Filed Mar 16, 2018 00:14 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 9,844 | $53.53 | $526,949.32 |
DisclosureSEC source: 0001209191-18-020025 · doc4.xml · nonDerivative · entry 4 Tamura Toshinari · CIK 0001621329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,000 Read SEC document |
| March 13, 2018 Filed Mar 16, 2018 00:14 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 14,156 | $53.26 | $753,948.56 |
DisclosureSEC source: 0001209191-18-020025 · doc4.xml · nonDerivative · entry 3 Tamura Toshinari · CIK 0001621329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,844 Read SEC document |
| March 13, 2018 Filed Mar 16, 2018 00:14 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 12,000 | $18.34 | $220,080.00 |
DisclosureSEC source: 0001209191-18-020025 · doc4.xml · nonDerivative · entry 2 Tamura Toshinari · CIK 0001621329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 13, 2018 Filed Mar 16, 2018 00:14 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 12,000 | $18.00 | $216,000.00 |
DisclosureSEC source: 0001209191-18-020025 · doc4.xml · nonDerivative · entry 1 Tamura Toshinari · CIK 0001621329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2017 Filed Jun 13, 2017 23:32 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $9.78 | $0.00 |
DisclosureSEC source: 0001209191-17-039686 · doc4.xml · derivative · entry 10 Tamura Toshinari · CIK 0001621329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2023-04-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested. Read SEC document |
| June 12, 2017 Filed Jun 13, 2017 23:32 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0001209191-17-039686 · doc4.xml · derivative · entry 9 Tamura Toshinari · CIK 0001621329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,000 shares Expires 2022-06-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested. Read SEC document |
| June 12, 2017 Filed Jun 13, 2017 23:32 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 15,000 | $28.57 | $428,550.00 |
DisclosureSEC source: 0001209191-17-039686 · doc4.xml · nonDerivative · entry 6 Tamura Toshinari · CIK 0001621329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,000 F2 · price: The shares were sold at prices ranging from $28.50 to $28.80. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 12, 2017 Filed Jun 13, 2017 23:32 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 12,000 | $9.78 | $117,300.00 |
DisclosureSEC source: 0001209191-17-039686 · doc4.xml · nonDerivative · entry 5 Tamura Toshinari · CIK 0001621329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2017 Filed Jun 13, 2017 23:32 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 3,000 | $5.95 | $17,850.00 |
DisclosureSEC source: 0001209191-17-039686 · doc4.xml · nonDerivative · entry 4 Tamura Toshinari · CIK 0001621329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 09, 2017 Filed Jun 13, 2017 23:32 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0001209191-17-039686 · doc4.xml · derivative · entry 8 Tamura Toshinari · CIK 0001621329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires 2022-06-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested. Read SEC document |
| June 09, 2017 Filed Jun 13, 2017 23:32 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001209191-17-039686 · doc4.xml · derivative · entry 7 Tamura Toshinari · CIK 0001621329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2021-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested. Read SEC document |
| June 09, 2017 Filed Jun 13, 2017 23:32 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 15,000 | $29.20 | $438,000.00 |
DisclosureSEC source: 0001209191-17-039686 · doc4.xml · nonDerivative · entry 3 Tamura Toshinari · CIK 0001621329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,000 F1 · price: The shares were sold at prices ranging from $29.20 to $29.30. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 09, 2017 Filed Jun 13, 2017 23:32 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 3,000 | $5.95 | $17,850.00 |
DisclosureSEC source: 0001209191-17-039686 · doc4.xml · nonDerivative · entry 2 Tamura Toshinari · CIK 0001621329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 09, 2017 Filed Jun 13, 2017 23:32 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 12,000 | $3.50 | $42,000.00 |
DisclosureSEC source: 0001209191-17-039686 · doc4.xml · nonDerivative · entry 1 Tamura Toshinari · CIK 0001621329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 07, 2017 Filed Jun 9, 2017 22:44 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $28.65 | $0.00 |
DisclosureSEC source: 0001209191-17-039004 · doc4.xml · derivative · entry 1 Tamura Toshinari · CIK 0001621329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2027-06-07 F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable quarterly over one year measured from June 7, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.